81 related articles for article (PubMed ID: 1360315)
1. Antagonism of limbic and extrapyramidal actions of intracerebrally injected dopamine by ergolines with partial D2 agonist activity in the rat.
Campbell A; Baldessarini RJ; Yeghiayan S
Brain Res; 1992 Oct; 592(1-2):348-52. PubMed ID: 1360315
[TBL] [Abstract][Full Text] [Related]
2. Effects of dopamine partial-agonist aminoergolines on dopamine metabolism in limbic and extrapyramidal regions of rat brain.
Baldessarini RJ; Marsh ER; Huston-Lyons D
Biochem Pharmacol; 1994 May; 47(10):1917-9. PubMed ID: 7911303
[TBL] [Abstract][Full Text] [Related]
3. Selective antidopaminergic effects of S(+)N-n-propylnoraporphines in limbic versus extrapyramidal sites in rat brain: comparisons with typical and atypical antipsychotic agents.
Campbell A; Yeghiayan S; Baldessarini RJ; Neumeyer JL
Psychopharmacology (Berl); 1991; 103(3):323-9. PubMed ID: 1676180
[TBL] [Abstract][Full Text] [Related]
4. S(+)Apomorphines. Selective inhibition of excitatory effects of dopamine injected into the limbic system of the rat.
Campbell A; Baldessarini RJ; Teicher MH; Neumeyer JL
Neuropharmacology; 1985 May; 24(5):391-9. PubMed ID: 4022264
[TBL] [Abstract][Full Text] [Related]
5. Dopamine receptors and ergot drugs. Evidence that an ergolene derivative is a differential agonist at subcortical limbic dopamine receptors.
Fuxe K; Fredholm BB; Agnati LF; Corrodi H
Brain Res; 1978 May; 146(2):295-311. PubMed ID: 647392
[TBL] [Abstract][Full Text] [Related]
6. Loss of D1/D2 dopamine receptor synergisms following repeated administration of D1 or D2 receptor selective antagonists: electrophysiological and behavioral studies.
Hu XT; White FJ
Synapse; 1994 May; 17(1):43-61. PubMed ID: 7913772
[TBL] [Abstract][Full Text] [Related]
7. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.
Breese GR; Duncan GE; Napier TC; Bondy SC; Iorio LC; Mueller RA
J Pharmacol Exp Ther; 1987 Jan; 240(1):167-76. PubMed ID: 3100767
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of dopamine agonists upon stimulated limbic and striatal dopamine release: in vivo voltammetric data.
Stamford JA; Kruk ZL; Millar J
Br J Pharmacol; 1991 Jan; 102(1):45-50. PubMed ID: 1675147
[TBL] [Abstract][Full Text] [Related]
9. Dopamine agonist action in mesolimbic, cortical and extrapyramidal areas to modify spontaneous climbing behaviour of the mouse.
Costall B; Eniojukan JF; Naylor RJ
Psychopharmacology (Berl); 1985; 86(4):452-7. PubMed ID: 3929317
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological profile of the dopamine partial agonist, (+/-)-PD 128483 and its enantiomers.
Meltzer LT; Caprathe BW; Christoffersen CL; Corbin AE; Jaen JC; Ninteman FW; Pugsley TA; Serpa KA; Shih YH; Whetzel SZ
J Pharmacol Exp Ther; 1993 Sep; 266(3):1177-89. PubMed ID: 8103791
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological characterization of the receptor mediating electrophysiological responses to dopamine in the rat medial prefrontal cortex: a microiontophoretic study.
Sesack SR; Bunney BS
J Pharmacol Exp Ther; 1989 Mar; 248(3):1323-33. PubMed ID: 2564893
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of antipsychotic and psychotomimetic drugs on neurotensin systems of discrete extrapyramidal and limbic regions.
Gygi SP; Gibb JW; Hanson GR
J Pharmacol Exp Ther; 1994 Jul; 270(1):192-7. PubMed ID: 7913495
[TBL] [Abstract][Full Text] [Related]
13. Mapping of locomotor behavioral arousal induced by microinjections of dopamine within nucleus accumbens septi of rat forebrain.
Campbell A; Villavicencio AT; Yeghiayan SK; Balikian R; Baldessarini RJ
Brain Res; 1997 Oct; 771(1):55-62. PubMed ID: 9383008
[TBL] [Abstract][Full Text] [Related]
14. Electrophysiological effects of putative autoreceptor-selective dopamine agonists on A10 dopamine neurons.
Ackerman JM; Johansen PA; Clark D; White FJ
J Pharmacol Exp Ther; 1993 May; 265(2):963-70. PubMed ID: 8098768
[TBL] [Abstract][Full Text] [Related]
15. S(+)methylenedioxy-N-n-propylnoraporphine: an orally active inhibitor of dopamine selective for rat limbic system.
Campbell A; Baldessarini RJ; Kula NS; Ram VJ; Neumeyer JL
Brain Res; 1987 Feb; 403(2):393-7. PubMed ID: 3828830
[TBL] [Abstract][Full Text] [Related]
16. [Selective analyzers of dopamine D2 receptors modulate serotonin metabolism in the striatum and nucleus accumbens of the rat brain during blockade of dopaminergic impulse flow].
Gaĭnetdinov RR; Bogdanov MB; Kudrin VS; Raevskiĭ KS
Biull Eksp Biol Med; 1992 Jun; 113(6):614-6. PubMed ID: 1359911
[TBL] [Abstract][Full Text] [Related]
17. Partial dopamine-agonistic and atypical neuroleptic properties of the amino-ergolines SDZ 208-911 and SDZ 208-912.
Coward DM; Dixon AK; Urwyler S; White TG; Enz A; Karobath M; Shearman G
J Pharmacol Exp Ther; 1990 Jan; 252(1):279-85. PubMed ID: 1967646
[TBL] [Abstract][Full Text] [Related]
18. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
Hu XT; White FJ
Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
[TBL] [Abstract][Full Text] [Related]
19. Dopamine supersensitivity and D1/D2 synergism are unrelated to changes in striatal receptor density.
LaHoste GJ; Marshall JF
Synapse; 1992 Sep; 12(1):14-26. PubMed ID: 1357762
[TBL] [Abstract][Full Text] [Related]
20. FCE 23884, substrate-dependent interaction with the dopaminergic system. I. Preclinical behavioral studies.
Buonamici M; Mantegani S; Cervini MA; Maj R; Rossi AC; Caccia C; Carfagna N; Carminati P; Fariello RG
J Pharmacol Exp Ther; 1991 Oct; 259(1):345-55. PubMed ID: 1681087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
